Skip to main content
Top
Published in: Abdominal Radiology 7/2021

01-07-2021 | Hepatic Encephalopathy | Interventional Radiology

The combination of Child–Pugh score and quantitative CT-based spleen volume could predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation

Authors: Jiacheng Liu, Chen Zhou, Yingliang Wang, Chongtu Yang, Qin Shi, Songjiang Huang, Yang Chen, Tongqiang Li, Bin Xiong

Published in: Abdominal Radiology | Issue 7/2021

Login to get access

Abstract

Purpose

Hepatic encephalopathy (HE) is a common complication in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS). The objective of this study was to assess the prognostic factors and make risk stratification of post-TIPS HE.

Methods

This was a retrospective cohort study consisting of cirrhotic patients who had undergone TIPS creation at our center from November 2015 to August 2020. The baseline characteristics including spleen volume (SVol) and other markers were collected. The univariate and multivariate Cox regression analyses were used to identify independent predictors of post-TIPS overt HE (OHE).

Results

Higher Child–Pugh (CP) score (HR 1.334, 95% CI 1.090–1.632, P = 0.005) and smaller SVol (HR 0.999, 95% CI 0.997–1.000, P = 0.004) were identified as the independent risk factors for post-TIPS OHE. And a time-dependent ROC analysis was used to determine the cutoff values of CP score and SVol, which were respectively 6.5 and 773 cm3. Subsequently, the CP-SVol grading system was developed to divide patients into three risk grades according to the above two cutoff values. Kaplan–Meier analysis showed that the cumulative rates of patients free of OHE in Grade 1, 2 and 3 were respectively 96.4% ± 3.5%, 82.1 ± 4.7%, and 59.3% ± 6.4%, which were in descending order (Log rank P < 0.001).

Conclusion

SVol might be a novel marker to predict the prognosis of post-TIPS OHE, and the proposed CP-SVol grading system composed of CP score and SVol achieved a superior predictive performance.
Literature
1.
2.
go back to reference Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012 Feb;16(1):133-46.CrossRef Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012 Feb;16(1):133-46.CrossRef
3.
go back to reference Rössle M, Haag K, Ochs A, Sellinger M, Nöldge G, Perarnau JM, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med. 1994 Jan 20;330(3):165-71.CrossRef Rössle M, Haag K, Ochs A, Sellinger M, Nöldge G, Perarnau JM, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med. 1994 Jan 20;330(3):165-71.CrossRef
4.
go back to reference Nolte W, Wiltfang J, Schindler C, Münke H, Unterberg K, Zumhasch U, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology. 1998 Nov;28(5):1215-25.CrossRef Nolte W, Wiltfang J, Schindler C, Münke H, Unterberg K, Zumhasch U, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology. 1998 Nov;28(5):1215-25.CrossRef
5.
go back to reference Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008 Nov;103(11):2738-46.CrossRef Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008 Nov;103(11):2738-46.CrossRef
6.
go back to reference Casadaban LC, Parvinian A, Minocha J, Lakhoo J, Grant CW, Ray CE Jr, et al. Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes. Dig Dis Sci. 2015 Apr;60(4):1059-66.CrossRef Casadaban LC, Parvinian A, Minocha J, Lakhoo J, Grant CW, Ray CE Jr, et al. Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes. Dig Dis Sci. 2015 Apr;60(4):1059-66.CrossRef
7.
go back to reference Fonio P, Discalzi A, Calandri M, Doriguzzi Breatta A, Bergamasco L, Martini S, et al. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification. Radiol Med. 2017 Sep;122(9):713-721.CrossRef Fonio P, Discalzi A, Calandri M, Doriguzzi Breatta A, Bergamasco L, Martini S, et al. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification. Radiol Med. 2017 Sep;122(9):713-721.CrossRef
8.
go back to reference Mas A. Hepatic encephalopathy: from pathophysiology to treatment. Digestion. 2006;73 Suppl 1:86-93.CrossRef Mas A. Hepatic encephalopathy: from pathophysiology to treatment. Digestion. 2006;73 Suppl 1:86-93.CrossRef
9.
go back to reference Jaffe A, Lim JK, Jakab SS. Pathophysiology of Hepatic Encephalopathy. Clin Liver Dis. 2020 May;24(2):175-188.CrossRef Jaffe A, Lim JK, Jakab SS. Pathophysiology of Hepatic Encephalopathy. Clin Liver Dis. 2020 May;24(2):175-188.CrossRef
10.
go back to reference Orlando R, Lirussi F, Basso SM, Lumachi F. Splenomegaly as risk factor of liver cirrhosis. A retrospective cohort study of 2,525 patients who underwent laparoscopy. In Vivo. 2011 Nov-Dec;25(6):1009-12. Orlando R, Lirussi F, Basso SM, Lumachi F. Splenomegaly as risk factor of liver cirrhosis. A retrospective cohort study of 2,525 patients who underwent laparoscopy. In Vivo. 2011 Nov-Dec;25(6):1009-12.
11.
go back to reference Shah SH, Hayes PC, Allan PL, Nicoll J, Finlayson ND. Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portal hypertension due to hepatic cirrhosis. Am J Gastroenterol. 1996 Dec;91(12):2580-3.PubMed Shah SH, Hayes PC, Allan PL, Nicoll J, Finlayson ND. Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portal hypertension due to hepatic cirrhosis. Am J Gastroenterol. 1996 Dec;91(12):2580-3.PubMed
12.
go back to reference Cheng YF, Huang TL, Chen TY, Concejero A, Tsang LL, Wang CC, et al. Liver graft-to-recipient spleen size ratio as a novel predictor of portal hyperperfusion syndrome in living donor liver transplantation. Am J Transplant. 2006 Dec;6(12):2994-9.CrossRef Cheng YF, Huang TL, Chen TY, Concejero A, Tsang LL, Wang CC, et al. Liver graft-to-recipient spleen size ratio as a novel predictor of portal hyperperfusion syndrome in living donor liver transplantation. Am J Transplant. 2006 Dec;6(12):2994-9.CrossRef
13.
go back to reference Cejna M, Peck-Radosavljevic M, Thurnher S A, Hittmair K, Schoder M, Lammer J. Creation of Transjugular Intrahepatic Portosystemic Shunts with Stent-Grafts: Initial Experiences with a Polytetrafluoroethylene-covered Nitinol Endoprosthesis. Radiology. 2001, 221(2): 437-446.CrossRef Cejna M, Peck-Radosavljevic M, Thurnher S A, Hittmair K, Schoder M, Lammer J. Creation of Transjugular Intrahepatic Portosystemic Shunts with Stent-Grafts: Initial Experiences with a Polytetrafluoroethylene-covered Nitinol Endoprosthesis. Radiology. 2001, 221(2): 437-446.CrossRef
14.
go back to reference Madoff DC, Gaba RC, Weber CN, Clark TW, Saad WE. Portal Venous Interventions: State of the Art. Radiology. 2016;278(2):333‐353.CrossRef Madoff DC, Gaba RC, Weber CN, Clark TW, Saad WE. Portal Venous Interventions: State of the Art. Radiology. 2016;278(2):333‐353.CrossRef
15.
go back to reference Robertson F, Leander P, Ekberg O. Radiology of the spleen. Eur Radiol. 2001;11(1):80-95.CrossRef Robertson F, Leander P, Ekberg O. Radiology of the spleen. Eur Radiol. 2001;11(1):80-95.CrossRef
16.
go back to reference Khoshpouri P, Hazhirkarzar B, Ameli S, Pandey A, Ghadimi M, Rezvani Habibabadi R, et al. Quantitative spleen and liver volume changes predict survival of patients with primary sclerosing cholangitis. Clin Radiol. 2019 Sep;74(9):734.e13-734.e20.CrossRef Khoshpouri P, Hazhirkarzar B, Ameli S, Pandey A, Ghadimi M, Rezvani Habibabadi R, et al. Quantitative spleen and liver volume changes predict survival of patients with primary sclerosing cholangitis. Clin Radiol. 2019 Sep;74(9):734.e13-734.e20.CrossRef
17.
go back to reference American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014 Sep;61(3):642-59. American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014 Sep;61(3):642-59.
18.
go back to reference Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008 Oct;14 Suppl 2:S67-79.CrossRef Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008 Oct;14 Suppl 2:S67-79.CrossRef
19.
go back to reference Krishnarao A, Gordon FD. Prognosis of Hepatic Encephalopathy. Clin Liver Dis. 2020 May;24(2):219-229.CrossRef Krishnarao A, Gordon FD. Prognosis of Hepatic Encephalopathy. Clin Liver Dis. 2020 May;24(2):219-229.CrossRef
20.
go back to reference Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005 May;42(5):674-9.CrossRef Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005 May;42(5):674-9.CrossRef
21.
go back to reference Bai M, Qi X, Yang Z, Nie Y, Yuan S, Wu K, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol. 2011 Jun;26(6):943-51.CrossRef Bai M, Qi X, Yang Z, Nie Y, Yuan S, Wu K, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol. 2011 Jun;26(6):943-51.CrossRef
22.
go back to reference Merola J, Chaudhary N, Qian M, Jow A, Barboza K, Charles H, et al. Hyponatremia: A Risk Factor for Early Overt Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. J Clin Med. 2014 Apr 4;3(2):359-72.CrossRef Merola J, Chaudhary N, Qian M, Jow A, Barboza K, Charles H, et al. Hyponatremia: A Risk Factor for Early Overt Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. J Clin Med. 2014 Apr 4;3(2):359-72.CrossRef
23.
go back to reference . Chen L, Xiao T, Chen W, Long Q, Li R, Fang D, et al. Outcomes of transjugular intrahepatic portosystemic shunt through the left branch vs. the right branch of the portal vein in advanced cirrhosis: a randomized trial. Liver Int. 2009 Aug;29(7):1101-9. . Chen L, Xiao T, Chen W, Long Q, Li R, Fang D, et al. Outcomes of transjugular intrahepatic portosystemic shunt through the left branch vs. the right branch of the portal vein in advanced cirrhosis: a randomized trial. Liver Int. 2009 Aug;29(7):1101-9.
24.
go back to reference Lewis DS, Lee TH, Konanur M, Ziegler C, Hall MD, Pabon-Ramos WM, et al. Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. J Vasc Interv Radiol. 2019 Feb;30(2):163-169.CrossRef Lewis DS, Lee TH, Konanur M, Ziegler C, Hall MD, Pabon-Ramos WM, et al. Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. J Vasc Interv Radiol. 2019 Feb;30(2):163-169.CrossRef
25.
go back to reference Gioia S, Merli M, Nardelli S, Lattanzi B, Pitocchi F, Ridola L, et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. Liver Int. 2019 May;39(5):871-877.CrossRef Gioia S, Merli M, Nardelli S, Lattanzi B, Pitocchi F, Ridola L, et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. Liver Int. 2019 May;39(5):871-877.CrossRef
26.
go back to reference Wang Q, Lv Y, Bai M, Wang Z, Liu H, He C, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol. 2017 Sep;67(3):508-516.CrossRef Wang Q, Lv Y, Bai M, Wang Z, Liu H, He C, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol. 2017 Sep;67(3):508-516.CrossRef
27.
go back to reference Schepis F, Vizzutti F, Garcia-Tsao G, Marzocchi G, Rega L, De Maria N, Di Maira T, et al. Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2018 Jul;16(7):1153-1162.e7.CrossRef Schepis F, Vizzutti F, Garcia-Tsao G, Marzocchi G, Rega L, De Maria N, Di Maira T, et al. Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2018 Jul;16(7):1153-1162.e7.CrossRef
28.
go back to reference Cui J, Smolinski SE, Liu F, Xu D, Dulaimy K, Irani Z. Incrementally Expandable Transjugular Intrahepatic Portosystemic Shunts: Single-Center Experience. AJR Am J Roentgenol. 2018 Feb;210(2):438-446.CrossRef Cui J, Smolinski SE, Liu F, Xu D, Dulaimy K, Irani Z. Incrementally Expandable Transjugular Intrahepatic Portosystemic Shunts: Single-Center Experience. AJR Am J Roentgenol. 2018 Feb;210(2):438-446.CrossRef
29.
go back to reference Luo L, Fu S, Zhang Y, Wang J. Early diet intervention to reduce the incidence of hepatic encephalopathy in cirrhosis patients: post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) findings. Asia Pac J Clin Nutr. 2016;25(3):497-503.PubMed Luo L, Fu S, Zhang Y, Wang J. Early diet intervention to reduce the incidence of hepatic encephalopathy in cirrhosis patients: post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) findings. Asia Pac J Clin Nutr. 2016;25(3):497-503.PubMed
Metadata
Title
The combination of Child–Pugh score and quantitative CT-based spleen volume could predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation
Authors
Jiacheng Liu
Chen Zhou
Yingliang Wang
Chongtu Yang
Qin Shi
Songjiang Huang
Yang Chen
Tongqiang Li
Bin Xiong
Publication date
01-07-2021
Publisher
Springer US
Published in
Abdominal Radiology / Issue 7/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-021-02972-6

Other articles of this Issue 7/2021

Abdominal Radiology 7/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine